Russia Tests Unique Liver Cancer Drug
A new liver cancer drug, 'Gepatoren-MRNC,' has successfully completed its first and second phases of clinical trials in Russia, according to the country's chief oncologist. The drug, based on albumin spheres labeled with 188Re, is intended for treating both primary and metastatic liver cancer.
Consensus
- The drug 'Gepatoren-MRNC' has successfully completed the first and second phases of clinical trials.
- The drug is described as having no analogs in the world.
- The drug is based on albumin spheres labeled with 188 Re.
- The drug is intended for treating patients with primary and metastatic liver cancer.
- The information was provided by Andrey Krapin, the chief oncologist of the Russian Ministry of Health, in interviews with TASS.
Points of divergence
- Krapin previously spoke in an interview with IS 'Vesti' about the development of vaccines against oncological diseases by the National Medical Research Center of Radiology under the Ministry of Health of Russia. — visti
Coverage (3 sources)
- Russia successfully tested a liver cancer drug without world analogs — РИАМО
- Ministry of Health: Tests of unique liver cancer drug passed successfully — Вести
- New drug for liver cancer treatment "Gepatoren-MRNC" successfully completed first and second phases of clinical trials, ra... — ТАСС (Telegram)